$REVB

Revelation Biosciences (NASDAQ:REVB) reported financial results for the three and six months ended June 30, 2026. Cash and cash equivalents rose to $11.5M from $10.7M at Dec. 31, 2025, and it expects funding through Q1 2027. Net loss was $3.3M ($0.87/share) for Q2 and $6.3M ($3.41/share) for six months. The company also advanced Gemini AKI Phase 2/3 start-up and formed an AKI advisory board.

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-st

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 3 revb-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 RIGHTS AGREEMENT dated as of July 10, 2026 by and between REVELATION BIOSCIENCES, INC. and CONTINENTAL STOCK TRANSFER & TRUST CO. Table of Contents SECTION 1. Certain Definitions 3 SECTION 2. Appointment of Rights Agent 10 SECTION

Revelation Biosciences (NASDAQ:REVB) said its board adopted a stockholder rights plan and declared a dividend of one right per common share. Rights are payable to holders of record July 21, 2026. Rights generally become exercisable at 10% (15% for some passive investors) and expire after one year unless approved earlier.

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-3.1 2 revb-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 REVELATION BIOSCIENCES, INC. a Delaware corporation THIRD AMENDED AND RESTATED BYLAWS As Amended June 24, 2026 ARTICLE I: STOCKHOLDERS Section 1.1: Annual Meetings . If required by applicable law, an annual meeting of stockholders

Revelation Biosciences (NASDAQ:REVBW) reported a sharp drop in short interest in May. According to the article, short interest fell to 1,162 shares as of May 15 from 48,365 shares on April 30 (down 97.6%). The stock traded at about $0.01, up 19.6% on the day, with volume below its average.

Revelation Biosciences, Inc. has begun GMP manufacturing of GEMINI and a placebo to provide clinical drug supply for its later-stage clinical studies. This move is a critical step in advancing Revelation's pipeline and accelerating timelines for upcoming clinical programs, including randomized, double-blinded, placebo-controlled studies. The Company recently met with the FDA to discuss the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury.